Valneva SE (VALN) reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus vaccine candidate VLA1553. The company said the initial safety data generated in the trial VLA1553-321 showed that VLA1553 was generally safe and well tolerated in adolescents aged 12 to 17 years, regardless of previous CHIKV infection.